| Study characteristics | ADNI-1 | ADNI-GO (Grand Opportunities) |
ADNI-2 | ADNI-3 | |
| Primary goal | Develop biomarkers as outcome measures for clinical trials | Examine biomarkers in earlier stages of disease | Develop biomarkers as predictors of cognitive decline, and as outcome measures | Study the use of tau PET and functional imaging techniques in clinical trials | |
| Funding | $40 million federal (NIA), $27 million industry and foundation | $24 million American Recovery Act funds | $40 million federal (NIA), $27 million industry and foundation | $ 40 million federal (NIA), up to $20 million industry and foundation | |
| Duration/start date | 5 years/October 2004 | 2 years/September 2009 | 5 years/September 2011 | 5 years/September 2016 | |
| Cohort | 200 elderly controls
400 MCI 200 AD |
Existing ADNI-1 + 200 early MCI |
Existing ADNI-1 and ADNI-GO + 150 elderly controls100 early MCI 150 late MCI 150 AD |
Existing ADNI-1, ADNI-GO, ADNI-2 + 133 elderly controls 151 MCI 87 AD |
|
